Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

Waters Corporation and BD's Biosciences & Diagnostic Solutions business have announced a definitive agreement to combine in a $17.5 billion Reverse Morris Trust transaction, forming a new leader in life science and diagnostics. This strategic merger is projected to double Waters' total addressable market to $40 billion, generate pro forma 2025 sales of approximately $6.5 billion and adjusted EBITDA of $2.0 billion, and yield an estimated $345 million in annualized EBITDA synergies by 2030. The deal, expected to be accretive to adjusted EPS in the first year, aims to significantly increase recurring revenue and accelerate Waters' expansion into high-growth adjacencies, while BD will receive a $4 billion cash distribution to enhance its capital allocation.

Analysis

Waters Corporation (WAT) is set to fundamentally reshape its business through a $17.5 billion Reverse Morris Trust transaction with Becton, Dickinson and Company's (BDX) Biosciences & Diagnostic Solutions unit. This strategic combination is positioned as highly transformative for Waters, effectively doubling its total addressable market to approximately $40 billion and creating a life science leader with pro forma 2025 revenues of $6.5 billion. The financial outlook presented is robust, forecasting mid-to-high single-digit revenue growth, mid-teens annualized adjusted EPS growth, and 500 basis points of adjusted operating margin expansion over the next five years, supported by an anticipated $345 million in annualized EBITDA synergies by 2030. For Waters, the deal significantly increases its recurring revenue stream to over 70% and provides entry into high-growth adjacencies like flow cytometry and multiplex diagnostics. For BD, the transaction is a strategic divestiture designed to streamline its focus as a core medical technology company, while unlocking immediate shareholder value through a $4 billion cash distribution, at least half of which is earmarked for share repurchases. The neutral sentiment associated with BD suggests that while the capital return is a clear positive, the market is weighing the benefits of a more focused entity against the divestiture of a substantial business unit projected to generate $3.4 billion in 2025 revenue. The transaction, expected to close in Q1 2026, will leave existing Waters shareholders with approximately 60.8% ownership of the combined entity and introduces an initial net leverage ratio of 2.3x, a key metric to monitor throughout the integration process.

Key Decisions for Investors

• Investors in Waters (WAT) should assess this as a long-term growth and margin expansion opportunity, focusing on the company's ability to execute on the stated $345 million in synergies and manage the post-close net leverage of 2.3x.
• Becton, Dickinson (BDX) shareholders are receiving a stake in the new entity plus a significant capital return from the parent company; they should evaluate the value proposition of the more focused, post-divestiture BDX against the growth prospects of the spin-off.
• The transaction's value is heavily dependent on achieving ambitious long-term financial targets, so investors should monitor initial integration milestones, particularly the realization of the projected $200 million in cost synergies within the first three years post-closing.
• Given the extended timeline to a Q1 2026 close, both sets of investors must factor in potential risks from regulatory hurdles, changing market conditions, and the requirement for Waters' shareholder approval.